EDIT-102 / AbbVie, Editas Medicine - LARVOL DELTA

Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting (GlobeNewswire) - “Editas Medicine…announced that two scientific abstracts have been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held virtually May 1 – 7, 2021. The Company is presenting preclinical data on its Usher Syndrome 2A (USH2A) and retinitis pigmentosa 4 (RP4) programs…Gene edited USH2A exon 13 deletion restored USH2 protein complex expression and rescued deficits in photoreceptor morphology in human retinal organoids; and Clinically relevant levels of editing using a dual AAV CRISPR-Cas9 system as a therapeutic strategy for the treatment of RP4.”

Preclinical • Genetic Disorders • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update (GlobeNewswire, Editas Medicine, Inc.) - "Announcement of first patient dosing with EDIT-101 (AGN-151587) expected in 1Q20....EDIT-301 for Sickle Cell Disease and Beta-Thalassemia: IND filing for Sickle Cell Disease targeted by end of 2020."

IND • Trial status